Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.548
Peer-review started: September 20, 2014
First decision: November 19, 2014
Revised: December 10, 2014
Accepted: December 29, 2014
Article in press: December 29, 2014
Published online: March 27, 2015
Core tip: Despite reduction of hepatitis C prevalence, hemodialysis (HD) patients still comprise a high risk group. HD individuals with chronic hepatitis C virus infection have lower aminotransferase and viral levels, milder histological features and a lower frequency of cirrhosis and hepatocellular carcinoma. However, liver disease is related to higher cardiovascular and all-cause mortality in this patient population. According to current recommendations, choice of treatment is interferon or pegylated interferon, whilst low doses of ribavirin also seem to have promising results. Data regarding new protease inhibitors are still lacking.